1. Scrip
  2. >>Therapy Areas
  3. >>Blood and Clotting

Apellis’ Empaveli Data In Frontline PNH Incremental, But Still Helpful

Data Could Aid Uptake Despite Already Broad Label

 
• By Alaric DeArment

While the drug appears more efficacious than Alexion’s C5 inhibitors, those drugs could prove difficult to dethrone given how entrenched they are in PNH therapy.

Render illustration of Clinical Trial title on medical documents
Results of Apellis' PRINCE study of Empaveli seen as having incremental benefit for already-approved drug • Source: Shutterstock

Phase III data for Apellis Pharmaceuticals, Inc.’s C3 inhibitor Empaveli (pegcetacoplan) in treatment-naïve paroxysmal nocturnal hemoglobinuria (PNH) appear to offer a largely incremental benefit for the drug given that its broad label already includes such patients. Nevertheless, the data are expected to help with the drug’s uptake, though Alexion Pharmaceuticals Inc.’s C5 inhibitors Soliris (eculizumab) and Ultomiris (ravulizumab-cwvz) are sufficiently entrenched that they could prove difficult to unseat despite Empaveli showing what appears to be better efficacy.

The Waltham, MA-based Apellis and Stockholm-based Swedish Orphan Biovitrum AB (Sobi) announced on 25 May topline results from the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Blood and Clotting

BMS/Pfizer To Sell Discounted Eliquis Direct – And Other Drugmakers May Follow Suit

 
• By Alaric DeArment

Analysts see the new strategy as a way to address pressure from the Trump administration’s most favored nation drug pricing proposals.

Hopes Rise For Sickle Cell Gene Therapy Access As 33 States Join CMS Program

 
• By Alaric DeArment

CMS said that 33 US states plus the District of Columbia and Puerto Rico had joined a program whereby the agency negotiates outcomes-based contracts on their behalf.

BioMarin’s Roctavian Continues to Shine In Hemophilia A Despite Commercial Woes

 
• By Sushmita Panda

Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.

Pfizer’s Hympavzi Poised For Broader Hemophilia Label

 
• By Alaric DeArment

The drugmaker announced positive topline results for the drug in hemophilia A and B patients with inhibitors, on top of the existing approval for patients without inhibitors.

More from Therapy Areas

Memo Therapeutics Plans BK Virus Therapy Phase III Despite Trial Miss

 
• By Manas Mishra

Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

 
• By Joseph Haas

In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By Kevin Grogan

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.